Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
prednisone + chloroquine
- Development stage
- Phase 4
- Lead developer
- Bayer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of prednisone (a corticosteroid) and chloroquine (an antimalarial drug). This combination has been studied as an alternative treatment for autoimmune hepatitis (AIH), particularly for patients who are non-responders or partial responders to standard therapy, or who experience side effects from standard treatments. It has also been used in treating lupus to reduce the amount of steroid needed to control symptoms.
02
Targets
GR (Glucocorticoid receptor)β-Hematin
Beyond the preview
Go deeper on prednisone + chloroquine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on prednisone + chloroquine.